Journal Scans
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: a Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alpha-2b
Role of Bevacizumab and IFN in Metastatic Carcinoid Tumors
JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, K Hess, C Ng, JL Abbruzzese, JA Ajani
20080210
2008 Mar 10
J Clin Oncol
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: a Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alpha-2b
J Clin Oncol. 2008 Mar 10;26(8):1316-1323, JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, K Hess, C Ng, JL Abbruzzese, JA Ajani
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Carcinoid tumors, which arise from neuroendocrine cells, usually are indolent but can be difficult to treat once the disease becomes metastatic. Because no approved cytotoxic therapy is currently available in the United States to treat patients with metastatic carcinoid tumors, intervention at this point is limited to symptomatic treatment with octreotide. In Europe, interferon alfa (IFN) has been approved for use on the basis of improved time to progression compared with that of octreotide alone....
